Community/Retail

Craig Beavers highlights 3 major developments in cardiovascular and cardiometabolic medicine that pharmacists should have on their radar.

Joe DePinto of McKesson discusses how payers, providers, and employers diverge on CGT reimbursement—and why outcomes-based payment models may hold the key to broader patient access.

As Novo Nordisk transitions patients from Rybelsus to newer, higher-efficacy oral semaglutide formulations, pharmacists are on the front lines of counseling, dosing clarification, and adverse effect management.

Bundibugyo Ebola spreads in DRC and Uganda as the WHO declares a public health emergency of international concern; learn the case counts, travel alerts, and pharmacist readiness steps.

Clinical pharmacists may play an increasingly important role in longitudinal metabolic care, medication optimization, patient education, and multidisciplinary peptide management.

Spencer Durham, PharmD, FCCP, BCPS, BCIDP, discusses why hepatitis B remains an active public health threat.

The approval ends a decades-long gap in care for patients with chronic hepatitis delta virus (HDV) infection, a serious and life-threatening coinfection with hepatitis B that can rapidly progress to cirrhosis, liver cancer, and liver failure.

A board-certified psychiatric pharmacist breaks down how systemic fragmentation, access barriers, and policy gaps are undermining schizophrenia treatment—and what must change.

Community pharmacists emerged as the critical clinical link in the modern patient care continuum

Natalie Bellini, DNP, FNP-BC, BC-ADM, breaks down how updated ADA guidelines have broadened eligibility for continuous glucose monitors, automated insulin delivery systems, and continuous ketone monitoring.

If approved for this indication, finerenone would become the first nonsteroidal mineralocorticoid receptor antagonist indicated for adults with type 1 diabetes and CKD.

On World Schizophrenia Day, a psychiatric pharmacist details how EHR fragmentation drives medication errors in schizophrenia care, and why provider recognition is essential to fixing it.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists should approach continuous glucose monitoring (CGM) report review and explains why individualized patient education is key.

A large prospective cohort study offers pharmacists and clinicians new data to consider when counseling patients on the long-term value of early antiviral treatment.

Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, explains how pharmacists can better leverage underutilized continuous glucose monitoring (CGM) app features and address the education gaps that prevent patients from achieving long-term CGM persistence.

Pharmacists can use immunization registry data, collaborative practice agreements, and evidence-based vaccine advocacy to close adult hepatitis B care gaps.

Identifying inappropriate OTC medications and recommending safer pharmacotherapy treatments are important roles for pharmacists.

Eli Lilly's investigational triple hormone receptor agonist achieved average weight loss of up to 70.3 lb over 80 weeks.

A retrospective cohort study determined that individuals who consumed less than 1.0 g/kg/day of protein had significantly better kidney-related outcomes over 15 years of follow-up.

Expert highlights why hepatitis B vaccination remains an urgent priority for adult patients and why the 2-dose Heplisav-B regimen's faster seroprotection offers meaningful public health advantages over the traditional 3-dose series.

Nicole C. Pezzino, PharmD, BCACP, CDCES, explains why reimbursement gaps, workflow constraints, and the emotional burden of wearing a continuous glucose monitor (CGM) are limiting CGM success and how pharmacists can improve outcomes.

Use 5 checks to keep your emergency fund right-sized, earning more, and separated—so setbacks don’t wreck your finances.

Prior authorizations, injection site shortages, and care transition failures are undermining LAI antipsychotic adherence in patients with schizophrenia, one pharmacist explains.

Neurology trial tests low-dose lithium for MCI and Alzheimer risk; results miss primary end points but hint at slower verbal memory decline.

As agentic AI enters clinical workflows, the real risk isn't processing power—it's whether AI systems can consistently access authoritative, real-time medication intelligence.

Researchers at Northwestern University have uncovered a surprising new role for montelukast that could reshape how oncologists approach immunotherapy resistance.

Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP, explores the most significant advancements in continuous glucose monitoring (CGM) and automated insulin delivery in 2026.

The drug is currently under priority review by the FDA with a final decision expected by June 16, 2026.